KRAS and colorectal cancer: For example, pre-clinical studies demonstrated that combined rapamycin and L-asparaginase, which depletes cells of both glutamine and asparagine, can synergistically inhibit the growth of KRAS-mutant colorectal cancer cells that have upregulated asparagine synthetase [64].